Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNC013
MIFTS: 47

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Pancreatic Ductal Carcinoma

About this section

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 15
Carcinoma, Pancreatic Ductal 43 71
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 54
Pancreatic Duct Cancer 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:3587
ICD9CM 34 157.3
MeSH 43 D021441
SNOMED-CT 67 93939009
ICD10 32 C25.3
UMLS 71 C0153461 C0887833
Sources

Summaries for Pancreatic Ductal Carcinoma

About this section
Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to cystadenoma and ovarian serous carcinoma. An important gene associated with Pancreatic Ductal Carcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are HIV Life Cycle and GPCR Pathway. The drugs Axitinib and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include pancreatic duct, breast and pancreas, and related phenotypes are cellular and cardiovascular system

Sources

Related Diseases for Pancreatic Ductal Carcinoma

About this section

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 421)
# Related Disease Score Top Affiliating Genes
1 cystadenoma 30.3 MUC6 MUC5AC MUC1 KRT7 KRT20
2 ovarian serous carcinoma 30.3 TP53 ERBB2 CDH1
3 retinitis pigmentosa 11 30.2 TP53 EGFR CDKN2A
4 papillary adenocarcinoma 30.1 TP53 MUC1 KRT7 ERBB2 CDH1
5 acinar cell carcinoma 29.9 TP53 SMAD4 KRT7
6 mesothelioma, malignant 29.8 MUC1 MSLN KRT7 KRT20 CDKN2A CDH1
7 cystadenocarcinoma 29.7 VEGFA TP53 MUC5AC MUC2 MUC1 KRT7
8 in situ carcinoma 29.5 TP53 MUC1 ERBB2 EGFR EGF CDKN2A
9 tubular adenocarcinoma 29.4 MUC5AC MUC2 MUC1 KRT7 KRT20 ERBB2
10 pancreas disease 29.4 VEGFA TP53 SMAD4 EGFR
11 pancreatic ductal adenocarcinoma 29.3 VEGFA TP53 SMAD4 MUC1 MSLN ERBB2
12 adenoma 29.2 TP53 SMAD4 MUC6 MUC5AC MUC1 KRT7
13 mucoepidermoid carcinoma 28.9 TP53 MUC6 MUC5AC MUC2 MUC1 KRT7
14 adenocarcinoma 28.5 VEGFA TYMP TP53 SMAD4 MUC1 KRT7
15 breast ductal carcinoma 28.5 VEGFA TP53 SMAD4 MUC5AC MUC1 KRT7
16 ovarian serous cystadenocarcinoma 28.2 VEGFA TP53 SMAD4 MUC6 MUC5AC MUC1
17 pancreatic adenocarcinoma 27.6 VEGFA TYMP TP53 SMAD4 MUC6 MUC5AC
18 lung cancer susceptibility 3 27.1 VEGFA TYMP TP53 SMAD4 MUC5AC MUC1
19 pancreatic cancer 26.9 VEGFA TYMP TP53 TGM2 SMAD4 MUC6
20 ovarian cancer 26.3 VEGFA TYMP TP53 TGM2 SMAD4 MUC5AC
21 pancreatic adenosquamous carcinoma 11.4
22 scrotum paget's disease 10.7 MUC1 KRT7
23 urethral villous adenoma 10.6 KRT7 KRT20
24 intrahepatic biliary papillomatosis 10.6 MUC5AC MUC1
25 cervical basaloid squamous cell carcinoma 10.6 KRT7 CDKN2A
26 pancreatic serous cystadenocarcinoma 10.6 KRT7 KRT20
27 intrahepatic bile duct adenoma 10.6 KRT7 KRT20
28 seminal vesicle adenocarcinoma 10.6 KRT7 KRT20
29 gastric signet ring cell adenocarcinoma 10.6 KRT7 KRT20
30 nephrogenic adenoma of urinary bladder 10.6 KRT7 KRT20
31 malignant spiradenoma 10.6 TP53 KRT7
32 cap polyposis 10.6 MUC5AC MUC2
33 ovarian large-cell neuroendocrine carcinoma 10.6 KRT7 KRT20
34 inverted transitional papilloma 10.6 KRT7 CDKN2A
35 endometrial transitional cell carcinoma 10.6 KRT7 CDKN2A
36 anal canal paget's disease 10.6 KRT7 CDKN2A
37 small cell carcinoma of the bladder 10.6 KRT7 KRT20
38 aortic malignant tumor 10.6 KRT7 KRT20
39 urinary bladder small cell neuroendocrine carcinoma 10.6 KRT7 KRT20
40 anus basaloid carcinoma 10.6 KRT7 CDKN2A
41 cervical adenoid cystic carcinoma 10.6 KRT7 CDKN2A
42 cystitis cystica 10.6 KRT7 KRT20
43 middle ear adenoma 10.6 MUC1 KRT7
44 vulvar eccrine porocarcinoma 10.6 MUC1 CDKN2A
45 bile duct mucoepidermoid carcinoma 10.6 MUC5AC MUC1 KRT7
46 benign breast adenomyoepithelioma 10.6 KRT7 EGFR
47 jejunal adenocarcinoma 10.6 KRT7 KRT20
48 mucinous tubular and spindle renal cell carcinoma 10.5 MUC6 MUC1 KRT7
49 colonic lymphangioma 10.5 MUC1 KRT7 KRT20
50 krukenberg carcinoma 10.5 MUC1 KRT7 KRT20

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma
Sources

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

About this section

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 CDH1 CDKN2A CXCL12 DNM2 EGFR ERBB2
2 cardiovascular system MP:0005385 10.22 CDH1 CDKN2A CXCL12 DNM2 EGFR ERBB2
3 homeostasis/metabolism MP:0005376 10.18 CDH1 CDKN2A DNM2 EGFR ERBB2 KRT7
4 digestive/alimentary MP:0005381 10.17 CDH1 CDKN2A DNM2 EGF EGFR ERBB2
5 immune system MP:0005387 10.17 CDH1 CDKN2A CXCL12 DNM2 EGF EGFR
6 endocrine/exocrine gland MP:0005379 10.1 CDH1 CDKN2A EGF EGFR ERBB2 MUC2
7 muscle MP:0005369 9.86 CDKN2A CXCL12 DNM2 EGFR ERBB2 SMAD4
8 neoplasm MP:0002006 9.81 CDH1 CDKN2A EGFR ERBB2 MUC2 SMAD4
9 no phenotypic analysis MP:0003012 9.5 CDH1 CDKN2A CXCL12 EGFR TGM2 TP53
10 normal MP:0002873 9.32 CDH1 CXCL12 DNM2 EGF EGFR ERBB2
Sources

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

About this section

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
5 Protein Kinase Inhibitors Phase 3
6 Immunologic Factors Phase 3
7 Anti-Infective Agents Phase 3
8 Albumin-Bound Paclitaxel Phase 3
9 Antimitotic Agents Phase 3
10 Antiviral Agents Phase 3
11 Immunosuppressive Agents Phase 3
12 Antimetabolites Phase 3
13 Viscosupplements Phase 3
14 Protective Agents Phase 3
15 Adjuvants, Immunologic Phase 3
16
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
19
Enoxaparin Approved Phase 2 9005-49-6 772
20
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
21
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
24
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
25 Gastrointestinal Agents Phase 2
26 Antineoplastic Agents, Immunological Phase 2
27 Topoisomerase Inhibitors Phase 2
28 Autonomic Agents Phase 2
29 HIV Protease Inhibitors Phase 2
30
protease inhibitors Phase 2
31 Antiemetics Phase 2
32 Hormone Antagonists Phase 2
33 BB 1101 Phase 2
34 Anti-Inflammatory Agents Phase 2
35 Antineoplastic Agents, Hormonal Phase 2
36 glucocorticoids Phase 2
37 Hormones Phase 2
38 Anti-Bacterial Agents Phase 2
39 Antibiotics, Antitubercular Phase 2
40
Liposomal doxorubicin Phase 2 31703
41 Pharmaceutical Solutions Phase 2
42
s 1 (combination) Phase 2
43
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
44
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
45
Durvalumab Approved, Investigational Phase 1 1428935-60-7
46
Etoposide Approved Phase 1 33419-42-0 36462
47
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 6857599 43805
48
leucovorin Approved Phase 1 58-05-9 6006 143
49
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
50
Fluorouracil Approved Phase 1 51-21-8 3385

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;Gemcitabine;placebo
2 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
4 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Unknown status NCT02529579 Phase 1, Phase 2 Gemcitabine
5 Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
6 A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer Completed NCT00226746 Phase 2 Paclitaxel and gemcitabine
7 A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
8 A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer Completed NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
9 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
10 An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
11 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
12 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
13 Panitumumab in Combination With Cisplatin/Gemcitabine Chemotherapy in Patients With Cholangiocarcinomas - a Randomized Clinical Phase II Study Completed NCT01320254 Phase 2 Cisplatin, Gemcitabine, Panitumumab;Cisplatin, Gemcitabine
14 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Recruiting NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
15 Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma - A Randomized Controlled Trial Not yet recruiting NCT04146441 Phase 2 Chemotherapy
16 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
17 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007
18 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. Completed NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
19 A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed NCT02259114 Phase 1 MK-8628
20 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Recruiting NCT04045496 Phase 1 JAB-3312
21 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
22 A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors Active, not recruiting NCT02646748 Phase 1 Pembrolizumab;itacitinib;INCB050465
23 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Not yet recruiting NCT04121286 Phase 1 JAB-3312
24 To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells Unknown status NCT02451384
25 An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy Unknown status NCT02310230
26 CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study Completed NCT00588367
27 Continuous Monitoring of Vital Signs in Hospitalized Patients Completed NCT02933307
28 Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence Completed NCT02150746
29 Prospective Populationbased Study on Pancreatic Cancer in Stockholm- Mutation Profiling Characteristics, Biobanking and Risk Factors. Completed NCT02162823
30 Endoscopic Retrograde CholangioPancreatography Endomicroscopy Registry Outcomes Database Completed NCT00779688
31 Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study Recruiting NCT02750657
32 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Recruiting NCT02817308
33 Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy Recruiting NCT02928081
34 Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1): a Multicenter Stepped-wedge Cluster Randomized Controlled Trial Recruiting NCT03513705
35 Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study Recruiting NCT03500068
36 Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial Recruiting NCT03257150 18F-Fluoroazomycin arabinoside
37 A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer Not yet recruiting NCT03432624
38 Evaluation of Safety and Feasibility of Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) for Solid Pancreatic Neoplasms Not yet recruiting NCT03435770
39 A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Terminated NCT01413451 Early Phase 1 Amatuximab (MORab-009)
40 Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients Terminated NCT02456051

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


gemcitabine
Gemcitabine hydrochloride

Cochrane evidence based reviews: carcinoma, pancreatic ductal

Sources

Genetic Tests for Pancreatic Ductal Carcinoma

About this section
Sources

Anatomical Context for Pancreatic Ductal Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

19
Pancreatic Duct

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

40
Breast, Pancreas, Lung, Colon, Kidney, Liver, Skin
Sources

Publications for Pancreatic Ductal Carcinoma

About this section

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 342)
# Title Authors PMID Year
1
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. 54 61
16951195 2006
2
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? 54 61
16018800 2005
3
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. 54 61
15725805 2005
4
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. 54 61
15084978 2004
5
MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. 54 61
14681945 2003
6
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. 54 61
12717266 2003
7
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. 54 61
11787853 2001
8
Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. 54 61
11391801 2001
9
Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. 54 61
11431719 2001
10
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives. 54 61
11391857 2001
11
NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. 61
31940589 2020
12
MCLA-128 Fights NRG1 Fusion-Positive Cancers. 61
31685488 2019
13
Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma. 61
31743881 2019
14
PACAP and PAC1 receptor expression in pancreatic ductal carcinoma. 61
31788045 2019
15
Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. 61
31786688 2019
16
Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. 61
31665640 2019
17
Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. 61
31404021 2019
18
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. 61
31527373 2019
19
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. 61
31533831 2019
20
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. 61
31164413 2019
21
ILF2 promotes anchorage independence through direct regulation of PTEN. 61
31423236 2019
22
Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. 61
31148345 2019
23
Primary non-ampullary duodenal follicular lymphoma presenting with obstructive jaundice. 61
31401784 2019
24
MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex. 61
31242384 2019
25
Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model. 61
31404387 2019
26
[MicroRNA-21 correlates TGF-β1 pathway of pancreatic ductal adenocarcinoma]. 61
31413212 2019
27
Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer. 61
31177164 2019
28
Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis. 61
31233118 2019
29
Mixed ductal-acinar cell carcinoma of the pancreas: A case report. 61
30967946 2019
30
Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma. 61
30776178 2019
31
[A Case Report of Conversion Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastasis after Chemotherapy]. 61
31164541 2019
32
Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. 61
30898113 2019
33
Diabetes of the exocrine pancreas. 61
30151918 2019
34
Invasive Ductal Carcinoma Arising in Mucinous Cystic Neoplasm of Pancreas: A Case Report. 61
30798329 2019
35
Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics. 61
31061821 2019
36
Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. 61
29249392 2019
37
Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies. 61
31679211 2019
38
Cytogenetic, Molecular, and Translational Applications in Pancreatic Ductal Adenocarcinoma: Current Evidence and Future Concepts. 61
31679207 2019
39
SMAD4 and TGFβR2 expression in pancreatic ductal carcinoma. 61
31912090 2019
40
Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. 61
31048929 2019
41
An Autopsy Case of Anaplastic Pancreatic Ductal Carcinoma (Spindle Cell Type) Multiple Onset in the Pancreas. 61
31123460 2019
42
A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy. 61
31887205 2019
43
Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis. 61
30336280 2018
44
Anaplastic pancreatic cancer diagnosed with endoscopic ultrasound guided fine needle aspiration showing hypervascular tumor: A case report. 61
30544436 2018
45
Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy. 61
30223034 2018
46
Small pancreatic ductal carcinomas on triple-phase contrast-enhanced computed tomography: enhanced rims and the pathologic correlation. 61
29796845 2018
47
Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure. 61
30515264 2018
48
Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. 61
30240298 2018
49
A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. 61
30326968 2018
50
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. 61
29492715 2018
Sources

Variations for Pancreatic Ductal Carcinoma

About this section
Sources

Expression for Pancreatic Ductal Carcinoma

About this section
Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.
Sources

Pathways for Pancreatic Ductal Carcinoma

About this section

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
HIV Life Cycle 65
Show member pathways
 13.72 SMAD4 MUC6 MUC5AC MUC2 MUC1 ERBB2
2
GPCR Pathway 63
Show member pathways
 13.7 VEGFA TYMP TP53 SMAD4 ERBB2 EGFR
3
ERK Signaling 63
Show member pathways
 13.7 VEGFA TYMP TP53 SMAD4 MUC1 ERBB2
4
Developmental Biology 65
Show member pathways
 13.5 VEGFA SMAD4 KRT7 KRT20 ERBB2 EGFR
5
TGF-Beta Pathway 63
Show member pathways
 13.5 VEGFA TYMP TP53 SMAD4 ERBB2 EGFR
6
PAK Pathway 63
Show member pathways
 13.3 TYMP SMAD4 ERBB2 EGFR EGF CXCL12
7
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.18 VEGFA TYMP ERBB2 EGFR EGF DNM2
8
Phospholipase-C Pathway 63
Show member pathways
 13.06 TYMP TP53 TGM2 EGFR EGF CXCL12
9
MAPK signaling pathway 36 1
12.76 VEGFA TP53 ERBB2 EGFR EGF
10
Endometrial cancer 36
Show member pathways
 12.67 VEGFA TP53 SMAD4 ERBB2 EGFR EGF
11
ErbB signaling pathway 1 36
Show member pathways
 12.61 VEGFA TP53 ERBB2 EGFR EGF
12
Glioma 36
Show member pathways
 12.58 TP53 ERBB2 EGFR EGF CDKN2A CDH1
13
MicroRNAs in cancer 36
12.51 VEGFA TP53 ERBB2 EGFR CDKN2A
14
Cytoskeletal Signaling 4
12.5 MUC1 KRT7 KRT20 DNM2 CDH1
15
Gastric cancer 36
Show member pathways
 12.42 TP53 SMAD4 MUC2 ERBB2 EGFR EGF
16
Development ERBB-family signaling 22
Show member pathways
 12.38 TP53 MUC1 ERBB2 EGFR EGF CDH1
17
Cell cycle 1 36
12.36 TP53 SMAD4 CDKN2A CDH1
18
Pathways in cancer 36
12.33 VEGFA TP53 SMAD4 ERBB2 EGFR EGF
19
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.31 TYMP ERBB2 EGFR EGF CXCL12 CDH1
20
Proteoglycans in cancer 36
12.3 VEGFA TP53 ERBB2 EGFR
21
O-linked glycosylation 65
Show member pathways
 12.24 MUC6 MUC5AC MUC2 MUC1
22
Diseases of glycosylation 65
Show member pathways
 12.11 MUC6 MUC5AC MUC2 MUC1
23
Integrated Breast Cancer Pathway 1
12.02 VEGFA TP53 SMAD4 EGFR CDH1
24
DNA Damage Response (only ATM dependent) 1
11.95 TP53 SMAD4 ERBB2 CDKN2A
25
Colorectal Cancer Metastasis 63
11.95 VEGFA TP53 SMAD4 EGFR EGF CDH1
26
Glioblastoma Multiforme 63
11.92 TP53 EGFR EGF CDKN2A
27
HIF-1 signaling pathway 36
11.91 VEGFA ERBB2 EGFR EGF
28
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) 65
Show member pathways
 11.9 MUC6 MUC5AC MUC2 MUC1
29
Signaling by ERBB4 65
Show member pathways
 11.88 ERBB2 EGFR EGF CXCL12
30
Endocytic Trafficking of EGFR 63
Show member pathways
 11.77 EGFR EGF DNM2
31
Platinum drug resistance 36
11.74 TP53 ERBB2 CDKN2A
32
G-protein signaling_RhoA regulation pathway 22
11.72 TYMP ERBB2 EGFR EGF CXCL12
33
Transcription_P53 signaling pathway 22
11.7 VEGFA TP53 SMAD4 CDKN2A
34
HIF-1-alpha transcription factor network 1
11.68 VEGFA SMAD4 CXCL12
35
Adherens junction 36
11.63 SMAD4 ERBB2 EGFR CDH1
36
Central carbon metabolism in cancer 36
11.6 TP53 SLC1A5 ERBB2 EGFR
37
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.59 SMAD4 ERBB2 EGFR EGF
38
HIF1Alpha Pathway 63
11.58 VEGFA TP53 CDKN2A
39
Photodynamic therapy-induced AP-1 survival signaling. 1
11.55 TP53 EGFR CDKN2A
40
Hepatitis C and Hepatocellular Carcinoma 1
11.55 VEGFA TP53 SMAD4
41
Thromboxane A2 receptor signaling 1
11.48 TGM2 EGFR EGF
42
Vemurafenib Pathway, Pharmacodynamics 60
11.46 VEGFA EGFR EGF
43
Signaling events mediated by TCPTP 1
Show member pathways
 11.45 VEGFA EGFR EGF
44
Stabilization and expansion of the E-cadherin adherens junction 1
11.41 EGFR EGF CDH1
45
Extracellular vesicle-mediated signaling in recipient cells 1
11.24 SMAD4 ERBB2 EGFR
46
a6b1 and a6b4 Integrin signaling 1
11.16 ERBB2 EGFR EGF CDH1
47
Bladder cancer 36 1
11.09 VEGFA TYMP TP53 ERBB2 EGFR EGF
48
G-protein signaling_Rap2B regulation pathway 22
10.99 TYMP ERBB2 EGFR EGF CXCL12 CDH1
49
Signaling by Overexpressed Wild-Type EGFR in Cancer 65
Show member pathways
 10.24 EGFR EGF
Sources

GO Terms for Pancreatic Ductal Carcinoma

About this section

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.97 TGM2 SLC1A5 MUC6 MUC5AC MUC2 MUC1
2 extracellular region GO:0005576 9.91 VEGFA MUC6 MUC5AC MUC1 MSLN EGFR
3 extracellular exosome GO:0070062 9.61 TGM2 SLC1A5 MUC5AC MUC1 KRT7 EGF
4 Golgi lumen GO:0005796 8.92 MUC6 MUC5AC MUC2 MUC1

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.93 VEGFA TP53 ERBB2 EGF CDKN2A
2 positive regulation of transcription, DNA-templated GO:0045893 9.87 TP53 SMAD4 EGFR EGF DNM2 CDKN2A
3 positive regulation of cell migration GO:0030335 9.86 VEGFA EGFR EGF CXCL12
4 positive regulation of epithelial cell proliferation GO:0050679 9.7 VEGFA ERBB2 EGFR
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.67 MUC6 MUC5AC MUC2 MUC1
6 regulation of cell motility GO:2000145 9.61 ERBB2 EGFR EGF
7 ERBB2 signaling pathway GO:0038128 9.58 ERBB2 EGFR EGF
8 positive regulation of MAP kinase activity GO:0043406 9.56 VEGFA ERBB2 EGFR EGF
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.55 TP53 EGFR
10 positive regulation of axon extension involved in axon guidance GO:0048842 9.51 VEGFA CXCL12
11 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.49 TP53 MUC1
12 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.48 VEGFA TP53
13 negative regulation of immature T cell proliferation in thymus GO:0033088 9.46 ERBB2 CDKN2A
14 O-glycan processing GO:0016266 9.46 MUC6 MUC5AC MUC2 MUC1
15 positive regulation of cell adhesion GO:0045785 9.26 VEGFA TGM2 ERBB2 CXCL12
16 negative regulation of ERBB signaling pathway GO:1901185 8.8 ERBB2 EGFR EGF

Molecular functions related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 VEGFA TP53 TGM2 SMAD4 SLC1A5 MUC6
2 growth factor activity GO:0008083 9.26 VEGFA TYMP EGF CXCL12
Sources

Sources for Pancreatic Ductal Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....